{"entity":{"id":"nct06619509","kind":"trial","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","aka":[],"tldr":"A phase 2 trial of Brigimadlin in advanced solid tumours, run by Boehringer Ingelheim, active and no longer recruiting.","summary":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine is a phase 2 interventional study registered as NCT06619509 by Boehringer Ingelheim, with 90 participants enrolled, started 2024-12-30 and due to reach its primary completion in 2030-12-30. Interventions recorded: Brigimadlin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06619509","url":"https://clinicaltrials.gov/study/NCT06619509"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["boehringer-ingelheim"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06619509","phase":"2","setting":"A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours","sponsor":"Boehringer Ingelheim","enrolled":90,"outcomes":[]},"route":"/trials/nct06619509/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/"}]}}